background: Decoy receptor 3 (DcR3) is a soluble receptor belonging to the tumor necrosis factor receptor superfamily and can inhibit Fas ligand-induced apoptosis. DcR3 is related to carcinogenesis, but is found in human gestational tissues, where the function is uncertain. We aimed to determine DcR3 expression and regulation in endometrial cells in vitro, and throughout the menstrual cycle and pregnancy in vivo. methods: Serum DcR3 levels were measured at various stages of the menstrual cycle (n ¼ 40 women) and pregnancy (n ¼ 20). DcR3 transcript and protein levels were analyzed in RL95-2 endometrial cells after treatment with estradiol (E 2 ) (+ anti-estrogen) and/or progesterone (+ anti-progesterone). Finally, DcR3 protein and transcript were examined in decidua and chorionic villi from normal (n ¼ 14) and anembryonic (n ¼ 14) pregnancies.
Introduction
Decoy receptor 3 (DcR3), also known as TR6 or M68, is a soluble molecule belonging to the tumor necrosis factor (TNF) receptor superfamily and was first characterized in lung and colon cancers (Pitti et al., 1998) . DcR3 acts as the receptor for Fas ligand (FasL), LIGHT and TL1A, all of which are expressed by activated T cells or natural killer cells (Green, 1998; Pitti et al., 1998; Connolly et al., 2001; Migone et al., 2002; Shi et al., 2003; Zhang et al., 2005) . DcR3 expression was initially believed to be restricted to tumor cells and its expression correlates with tumor grading and prognostic outcome (Pitti et al., 1998; Ohshima et al., 2000; Ibrahim et al., 2001; Roth et al., 2001; Takahama et al., 2002) . It has been postulated that DcR3 participates in the escape of cells from immune surveillance and thus facilitates tumor formation (Green, 1998; Pitti et al., 1998; Yu et al., 1999; Connolly et al., 2001; Roth et al., 2001; Li et al., 2005; Chen et al., 2008; Koksal et al., 2008; You et al., 2008) . Further evidence also indicates that DcR3 acts as a functional FasL decoy receptor and inhibits FasL-mediated apoptosis (Green, 1998; Pitti et al., 1998; Yu et al., 1999; Connolly et al., 2001; Roth et al., 2001) . Taken together, a number of tumors can escape FasL-mediated immune cytotoxic surveillance through the expression of DcR3 (Pitti et al., 1998) .
Although DcR3 plays an important role in the progression of malignant tumors, recent data also show the expression of DcR3 in some normal human tissues, including the spleen, lungs, gastrointestinal tract and the endothelial cells from umbilical veins (Pitti et al., 1998; Bai et al., 2000; Kim et al., 2000; Ashkenazi, 2002) , and that DcR3 may be involved in the pathophysiology of autoimmune diseases (Chang et al., 2006; Han et al., 2007; Hayashi et al., 2007; Lee et al., 2008) . Interestingly, significant expression of DcR3 occurs in the trout ovary and human gestational tissues, including human placental villi, cytotrophoblasts and placental macrophages (Bobe and Goetz, 2000; Phillips et al., 2001; Gill et al., 2002) . Since the mammalian fetus is considered a successful semi-allograft after implantation in the endometrium, the status and function of maternal immunomodulation can influence fetal survival (Thellin et al., 2000) . At the present time, it remains to be established how the semi-allograft successfully survives maternal immune surveillance, although a number of mechanisms are under intense investigation (Ho et al., 2001) . The significant expression of DcR3 in the placental tissues therefore supports the hypothesis that the semi-allograft overcomes the immune obstacle by utilizing the secreted decoy receptor to induce immune tolerance at the maternal-fetal interface.
Anembryonic pregnancies (blighted ovum) occur commonly in human gestation. Although chromosomal abnormalities of the fetuses likely account for many of these unfavorable clinical events, the mechanisms underlying the other cases mostly remain undefined. For these latter cases, it has long been suggested that abnormal immune modulation may play an important role. We therefore hypothesized that DcR3 expression in the endometrium and the maternal -fetal interface may be important in the regulation of successful embryo implantation and continuation of pregnancy. This study analyzed the expression of DcR3 in vivo during the human menstrual cycle and gestation, and in vitro using an endometrial cell line model treated with estradiol (E 2 ) and progesterone. Specifically, the expression and production of DcR3 in the maternal -fetal compartments were examined and compared between normal and anembryonic pregnancies. This study therefore has provided further information into the changes of DcR3 levels in human menstrual cycles and the regulation of DcR3 in endometrial cells by sex steroid hormones. Some evidence in this study also pointed to the potential role of DcR3 in pathologic pregnancies.
Materials and Methods

Collection and processing of serum samples and gestational tissues
For analysis of normal serum DcR3 levels, 40 normal cycling women (with a menstrual period of 27 -29 days) without any major diseases or hormone exposure in the past 3 months were enrolled in this study. Twenty women with normal pregnancies without detectable obstetrical or medical complications were also recruited. According to the last menstrual period, the basal body temperature chart and the serum E 2 and progesterone concentrations, serum samples from the same individual were collected sequentially during the early follicular phase (Days 1 -3 of the menstruation), the mid-follicular phase (Days 7 -9), at the time of ovulation (Days 13 -15), the mid-luteal phase (Days 20 -22) and during the next early follicular phase (Days 1 -3) (n ¼ 40). For each pregnant volunteer, serial serum samples were also collected at different gestational stages, including the first trimester (first to third month), the second trimester (fourth to sixth month), the third trimester (seventh to ninth month), immediately after delivery and early follicular phase of the first menstruation after delivery (n ¼ 20). All serum samples were processed and immediately stored at 2808C until measurement.
For analysis of gestational tissues, 14 women with normal viable pregnancies, who received elective surgical abortion in the first trimester for reasons such as multiparity, were enrolled in this study (the normal pregnancy group; n ¼ 14). Fourteen women with anembryonic pregnancies (blighted ovum) who underwent therapeutic abortion to terminate this pregnancy were also enrolled into this study (the anembryonic pregnancy group; n ¼ 14). All the normal or anembryonic pregnancies were 7 -10 weeks of gestation when the surgical abortions were performed. During surgery, the decidua and chorionic villi tissues were obtained and immediately sent to the laboratory for subsequent processing. The samples were washed three times with sterile phosphate-buffered saline (PBS) and were then minced into small pieces for preparation of proteins, RNA and paraffin block. Before study, the Institutional Review Board of National Taiwan University Hospital had reviewed and approved this project. In addition, informed consent was obtained from each volunteer or couple before participation in the study.
Rl95-2 endometrial cell line and culture
An epithelial cell line, RL95-2, derived from a moderately differentiated adenosquamous carcinoma of the endometrium, was obtained from the Food Industry Research and Development Institute (Taipei, Taiwan; BCRC No. 60103 ). The endometrial cell line was thawed and cultured in T-75 flasks (Falcon) in the medium (Dulbecco's modified Eagle's medium/F-12, 10 mM HEPES, 5 mg/ml bovine insulin, 2 g/l sodium bicarbonate and 10% fetal bovine serum) until confluence. The cells were then trypsinized and plated into each well of a six-well culture dishes (Falcon) at a concentration of 1 Â 10 6 cells/well/2 ml fresh medium and cultured at 378C with 5% CO 2 in humidified air for 24 h for attachment, when the medium was replaced with fresh medium and treatment started. The culture was allotted into several groups of treatment with E 2 and progesterone, alone or in combination for 24-28 h. Several doses of E 2 (50-1600 pg/ml; Sigma, St Louis, MO, USA) and progesterone (5-160 ng/ml; Sigma) were used in this study. In addition, in order to examine whether estrogen and progesterone effects on the expression of DcR3 in RL95-2 cells were nuclear receptor-mediated, anti-estrogen (tamoxifen citrate, 0.001 -0.1 mM; AstraZeneca, UK) and antiprogesterone (mifepristone, 0.001-0.1 mM; Roussel-Uclaf, Romainville, France) were also added to the RL95-2 cells. Hormone diluent alone was added in the 'zero' treatment groups. At the end of the experiment, the cells were trypsinized and collected for RNA extraction. For each experiment, each group of cells was cultured in duplicate and a mean value was obtained from the experimental data. The experiments were repeated at least three to five times for subsequent real-time PCR or western blot analysis.
Enzyme-linked immunosorbent assay
A DcR3 enzyme-linked immunosorbent assay (ELISA) kit (Anawrahta Company, Taipei, Taiwan) was used for the detection of DcR3 protein in the serum samples. The experimental procedures were performed according to the manufacturer's protocol. Briefly, samples, serially diluted standards and dilution buffer (200 ml for each) were put into each well of the detection plate and the plate was then incubated overnight at 48C. After washing with PBS-Tween 20 (0.05%) five times, biotinylated antibody was added and the plate was incubated for 2 h at room temperature with Decoy receptor 3 expression and hormone status gentle shaking. Following a wash procedure to remove the unbound biotinylated antibody, the streptavidin-horse-radish peroxidase was added to the wells and incubated at room temperature for 1 h with gentle shaking. After another wash, tetramethylbenzidine substrate solution was added to the wells and the color developed in proportion to the amount of bound DcR3. The intensity of the color was measured at the absorbance wavelength of 450 nm. All the specimens were examined in triplicate and a mean value was obtained for further analysis.
Immunohistochemical staining
Immunohistochemical staining (IHC) was performed to examine the location of DcR3 protein in the human decidua and chorionic villi. The IHC protocol was modified from the previous report (Chen et al., 2004) , and a Streptavidin/Biotin Universal Detection System (Immunotech, Marseille, France) was used. Briefly, formalin-fixed, paraffin-embedded tissue sections were deparaffinized with xylene and hydrated with step-down concentrations of ethanol. The sections were then incubated with 30% H 2 O 2 /70% methanol solution at room temperature for 5 min, blocked by 5% bovine serum albumin (BSA) dissolved in DakoCytomation antibody diluent (Dako North America, CA, USA) for 2 h at 378C and then incubated with mouse anti-human DcR3 antibodies (1:100 dilution; BioLegend, San Diego, CA, USA) at 378C in a humidified chamber overnight. On the next day, the sections were washed with PBS, treated with polyvalent biotinylated secondary antibody at room temperature for 10 min and then treated with streptavidin-peroxidase reagent at room temperature for 10 min. The color was developed using 3,3 0 -diaminobenzidine chromogen at room temperature for 15 min and counterstained with hematoxylin for 1 min. IHC was also done to confirm the expression of estrogen receptor (ER) and progesterone receptor (PR) in the RL95-2 endometrial cells. Briefly, RL95-2 cells cultured on coverslips were fixed with 4% paraformaldehyde and then went through procedures similar to those used for DcR3 examination described earlier. The primary antibodies included anti-ER antibody (SP1, rabbit monoclonal antibody; Ventana, Tucson, Arizona, USA) and anti-PR antibody (1E2, rabbit monoclonal antibody, Ventana, Tucson, Arizona, USA). For this IHC, negative controls including treatment without primary antibody and treatment with mouse isotype immunoglobulin IgG (mouse IgG negative/isotype control; AbD Serotec, Oxford, UK) were used. An independent pathologist who was blind to the origins of the samples reviewed these stained slides.
Western blot analysis
Proteins were extracted from the decidua and chorionic villi samples of gestation and the RL95-2 endometrial cells to examine the DcR3 protein levels. Briefly, harvested cells were washed three times with PBS, lysed in 1% sodium dodecyl sulfate (SDS), 1.0 mM sodium vanadate, 10 mM Tris, pH 7.4 solution containing protease inhibitor, homogenized by brief sonication (5 s/cycle, three cycles), and finally total protein content was determined. Subsequently, protein samples were separated by 10% SDS -polyacrylamide gel electrophoresis, transferred to polyvinylidene diflouride membranes (Amersham Pharmacia Biotech) and blocked by 5% BSA in 1Â Tris-buffered saline-Tween 20. The membranes were then probed sequentially with goat anti-human DcR3 polyclonal antibodies (Santa Cruz Biotechnology, Inc.) and anti-a-tubulin antibody (clone DM1A, Upstate), and then appropriate secondary antibodies (rabbit antigoat IgG; Chemicon; Temecula, CA, USA) conjugated with alkaline phosphatase. The positive bands were visualized with NBT/BCIP (nitro blue tetrazolium chloride/5-bromo-4-chloro-3-indolyl phosphate) substrate (Roche; Indianapolis, IN, USA) and the images were recorded by an Alpha Innotech IS1000 digital image system (San Leandro, CA, USA). In order to quantify the intensity of each band, the images were analyzed by a Fujifilm LAS-3000 Chemiluminescence System (Fujifilm Life Science; Stamford, CT, USA).
Standard PCR and real-time quantitative PCR
Standard PCR was used to detect the presence of DcR3 transcript in the decidua and chorionic villi. The primer set was: sense, 5 0 -TGCC GCCGAGACAGCCCCACGAC-3 0 ; antisense, 5 0 -GACGGCACGCTCA CACTCCTCAG-3 0 . The predicted size of the PCR product was 461 base pairs. Briefly, at pre-determined time points, tissues or cells were collected and treated with RLT lysis buffer (Qiagen). RNA was prepared and complementary DNA (cDNA) was obtained by random hexamer priming, as reported previously . The purity and concentration of RNA were analyzed by UV spectrophotometer, agarose gel electrophoresis and examination of the RT-PCR product of S26, a housekeeping gene. The PCR was carried out in a thermal cycler (GeneAmp PCR System 9700; Perkin-Elmer, Norwalk, CT, USA) as follows: denaturation at 948C for 30 s, annealing at 658C for 60 s, extension at 728C for 30 s and a final extension at 728C for 15 -30 min. The PCR was repeated for 35 cycles and the product was examined using 1.5% agarose gel electrophoresis and stained with SYBR green stain (SYBR Green I; Roche Molecular Biochemicals, Indianapolis, IN, USA). Several controls including an RT reaction without the addition of reverse transcriptase, and a PCR without template DNA, were used in the experiments. Real-time quantitative PCR was then used to quantify the relative DcR3 mRNA levels in the decidua, chorionic villi and RL95-2 endometrial cell samples. The preparations of RNA and cDNA were similar to those in standard PCR. The primers and probes used in the real-time PCR were selected from the Assay-On-Demand TM gene expression products (assay id: hs00187070_m1; Applied Biosystems) and the internal control was glyceraldehyde-3-phosphate dehydrogenase (assay id: hs99999905_m1; Applied Biosystems). Briefly, for each 50 ml reaction, 25 ml of 2Â TaqMan w Universal PCR Master Mix (Applied Biosystems) were mixed with 2.5 ml of 20Â Assay-On-Demand TM gene expression assay mix and 22.5 ml of cDNA diluted in RNase-free water. Subsequently, the PCR was carried out in a thermal cycler (ABI PRISM 7700 Sequence Detection System; Applied Biosystems) as follows: reaction at 508C for 2 min and 958C for 10 min; the PCR was repeated for 40 cycles of denaturation at 958C for 15 s and annealing and extension at 608C for 1 min. The authenticity of the PCR products was verified by 2% agarose gel electrophoresis and by direct sequencing. The resulting data were analyzed by SDS 1.9.1 software. Each sample was examined in triplicate and a mean value was obtained for further analysis. The relative concentration of each transcript was calculated using the rrC T method according to the manufacturer's user manual and previous publications Chen et al., 2004; Chen et al., 2007) . The experiments were repeated at least five times for subsequent statistical analysis.
Statistical analysis
A Student's t-test, paired t-test and one-way analysis of variance were used, where appropriate, for statistical analysis in this study. The SPSS Statistical Package (SYSTAT Software Inc.) was used to analyze these tests. A P-value ,0.05 was considered statistically significant.
Results
DcR3 levels throughout the menstrual cycle and gestation
The serum DcR3 levels during the menstrual cycles of 40 normal cycling women are presented in Fig. 1 . It was found that there was a borderline trend towards a higher DcR3 level in the mid-luteal phase (P ¼ 0.066, mid-luteal phase versus early follicular phase), and the level returned to a similar level in the early follicular phase of the next cycle. The serum levels of DcR3 were also examined in 20 subjects throughout gestation, immediately after delivery and after first menstruation (Fig. 1) . The serum DcR3 levels during gestation remained relatively low (0.2-0.4 ng/ml) with no major fluctuation when compared with the levels during normal menstrual cycles (1.4 -3.5 ng/ml). However, during early follicular phase of the first menstruation after delivery, the levels were similar to those in the early follicular phase of normal menstrual cycles.
The mRNA and protein levels of DcR3 in decidua and chorionic villi of normal or anembryonic pregnancies
DcR3 transcript and protein were detected in decidua and chorionic villi of normal and anembryonic pregnancies by RT-PCR (standard and real-time PCR) ( Fig. 2A and D) , and western blot analysis ( Fig. 2B and C) , and IHC (Fig. 3) , respectively. Quantification of the western blot data showed a higher level of DcR3 in the decidua than that in the chorionic villi of normal pregnancies (Fig. 2C) . Also, when comparing DcR3 in the decidua, the levels were significantly lower in anembryonic pregnancies than in normal pregnancies (Fig. 2C ). However, real-time PCR did not show significantly different transcript levels between groups, although the trend towards lower level in the decidua of anembryonic pregnancies remained (Fig. 2D ). IHC showed that the decidua presented with a more generalized immunoreactive DcR3 staining in the glandular and stromal cells in normal pregnancy (Fig. 3A) . In chorionic villi, the DcR3 staining was more intense but was localized to the cytotrophoblast cells and focal areas of syncytiotrophoblast cells (Fig. 3B) . Tissues from anembryonic pregnancies had similar DcR3 staining patterns ( Fig. 3C and  D) , but the levels in the decidua were less intense when compared with that of normal pregnancy ( Fig. 3A and C) . Negative controls without primary antibodies ( Fig. 3E and F ) and the use of isotype mouse IgG (Fig. 3G and H) , as expected, did not show immunostaining.
Hormonal regulation of DcR3 expression in RL95-2 endometrial cells
An endometrial cell line RL95-2 was used for in vitro experiments to provide further support for the serum DcR3 data in normal menstrual cycles and to further study the effect of female sex steroids. First, IHC showed the presence of ER and PR in the RL95-2 endometrial cells ( Fig. 4A-C ), suggesting that RL95-2 cells might be responsive to these hormones. Treatment with E 2 or progesterone alone stimulated DcR3 transcript expression by RL95-2 cells in a dose-dependent manner ( Fig. 4D and E ). This expression peaked at E 2 levels in the 400-1000 pg/ml range or a progesterone level of 40 ng/ml, levels comparable with the normal serum level during the mid-luteal phase. In contrast, the DcR3 transcript levels were suppressed at a high E 2 level (1600 pg/ml) or progesterone level !80 ng/ml. The combined effect of E 2 and progesterone was more complex (Fig. 4F ): E 2 (20 -400 pg/ml) and progesterone (5-20 ng/ml) were used concomitantly to mimic the physiologic environment in order to test their combined effects on RL95-2 endometrial cells. We found that E 2 and progesterone have a synergistic stimulatory effect on DcR3 mRNA at lower concentrations (Fig. 4F ). This effect, however, was blunted at an increasing progesterone dose, even when the E 2 dose was increased concomitantly. These dosedependent trends of E 2 and progesterone on the transcript expression were reflected at the DcR3 protein levels as shown by the western blot analysis, although hormone concentrations producing maximal protein stimulation might differ from those for transcripts ( Fig. 4G-I) . In the presence of progesterone (40 ng/ml), the use of anti-progesterone (mifepristone) exerted a dose-dependent suppression of DcR3 expression in the RL95-2 cells, which became statistically significant at a concentration of 0.1 mM of mifepristone (Fig. 4J) . However, the use of anti-estrogen (tamoxifen citrate) did not significantly alter the DcR3 expression in the presence of E 2 (800 pg/ml) (Fig. 4K ).
Discussion
This study identified a trend for cyclic serum DcR3 levels in the normal menstrual cycle, peaking in the mid-luteal phase. Although relatively low serum DcR3 levels persisted without significant changes throughout normal gestation, significantly different local production of DcR3 was found in the decidua when compared with the chorionic villi of normal pregnancy. Importantly, DcR3 protein levels in the decidua of anembryonic pregnancies were significantly lower than in normal pregnancies. In addition, in vitro experiments showed the stimulation of DcR3 expression in endometrial cells by physiologic doses of E 2 and/or progesterone. Overall, this study identified fluctuating DcR3 expression during the menstrual cycle and regulation of DcR3 expression by sex steroids in vitro in endometrial cells. Taken together with the defective production in the decidua of anembryonic pregnancies, these data supported an active role of DcR3 in the establishment and maintenance of human pregnancy.
The comparisons of serum DcR3 levels during different phases of normal menstrual cycles revealed only a trend for elevated DcR3 levels in the mid-luteal versus other phases. This could be due to the fact that the serum level, which is the systemic presentation of DcR3 from all sources, may not reflect accurately the local production in the endometrium. However, in vitro, a significant dose-dependent regulation of DcR3 expression in the RL95-2 endometrial cells by female sex steroids (E 2 and progesterone) further supported the observation of cyclic changes of serum DcR3 levels in vivo. Since during normal menstrual cycles the E 2 and progesterone levels fluctuate significantly, we speculate that the DcR3 levels are dynamically regulated in the endometrium to produce a suitable environment for the embryos to implant. The combined use of E 2 and progesterone in the in vitro treatment of RL95-2 endometrial cells was therefore intended to mimic the early follicular phase [E 2 /progesterone (20 pg/ml/0 ng/ml)], the time of ovulation (100/0), the early luteal phase (100/5), the late luteal phase (100/10) and early pregnancy (400/20). The levels of DcR3 expression at these time points basically followed a similar trend as the serum DcR3 levels in the normal menstrual cycle and during pregnancy. Taken together, the data suggested that low-to-moderate doses of E 2 and progesterone might have a mild synergistic stimulatory effect on DcR3 expression, especially in the mid-luteal phase when embryos normally implant in the endometrium. After a successful implantation, persistently adequate production of DcR3 in the resulting decidua will be important for the pregnancy to continue uneventfully. The cyclic change and sex steroid-regulated expression of DcR3 levels shown in this study therefore suggested the active role of DcR3 in human reproduction.
Anembryonic pregnancies are very common occurrences in early human pregnancies. It refers to the failure of progressive fetal and placental development after the embryo has initially implanted in the endometrium. We have previously identified that the production of interleukin 11 is defective in the decidua and chorionic villi of human anembryonic pregnancies , whereas other cytokines, such as leukemia inhibitory factor, are more related to the implantation stage, but not thereafter (Chen et al., 2004) . Since the present study showed that DcR3 production was significantly suppressed in the decidua of anembryonic pregnancies, these data may have identified a potentially important role of DcR3 expression in the pathophysiology of anembryonic pregnancies. At present, it remains unclear what led to defective DcR3 expression in the decidua, while at the same time the expression was not altered in the chorionic villi. However, the presumed explanations include the following. First, the endometrium or decidua of anembryonic pregnancies may have some inherent defects in response to the priming by female sex steroids or other factors/cytokines. Second, the fetal compartment may fail to present an instructive signal to induce the necessary DcR3 expression in the decidua. Considering the dose-dependent regulation of DcR3 in the RL95-2 endometrial cells by sex steroids, the first presumption is reasonable and will need to be explored in-depth. For this purpose, the first step would be to examine and compare the expression of DcR3 and its related ligand in vivo and in vitro in healthy subjects, patients with repeated implantation failure and/or patients with idiopathic recurrent spontaneous miscarriage. Taking together the data about peak DcR3 expression in the mid-luteal phase endometrium, when embryos normally implant, and the defective DcR3 production in the decidua of an anembryonic pregnancy, one may speculate that normal DcR3 expression in the endometrium is critical for the continuation of a successful pregnancy.
This study confirmed that ER and PR were present in the RL95-2 endometrial cells. This result was in line with the previous reports showing that RL95-2 cells, like the normal endometrium, expressed ER (Wadehra et al., 2008; Yang et al., 2008) and PR (Wadehra et al., 2008) . These data therefore supported the opinion that RL95-2 cells likely would be responsive to E 2 and progesterone treatment. Subsequent experiments confirmed this point by showing that, when used at the physiologic levels found during the menstrual cycle, E 2 and progesterone were stimulatory to DcR3 expression in the endometrial cells. Higher levels of E 2 or progesterone, on the contrary, appeared to have a suppressive effect on DcR3 in RL95-2 cells. The latter data probably could explain the observation of lower serum DcR3 levels during gestation, when E 2 and progesterone levels were normally higher. The demonstration of a dose-dependent progesterone antagonist-mediated suppression of DcR3 expression indicated that the action of progesterone in RL95-2 cells was receptormediated. However, the mechanism underlying the lack of antiestrogen (tamoxifen citrate) action on the DcR3 expression in the presence of E 2 is at present unclear. We propose that the concentration of tamoxifen citrate used in experiments could be one possible reason. In addition, since the effects of various anti-estrogens (for example, tamoxifen citrate and aromatase inhibitor) likely differ owing to different mechanisms of action, further studies will be needed to clarify these. In addition, this study revealed that nonphysiologic, high levels of E 2 and progesterone, singly or combined, could suppress DcR3 expression. These extremely high levels of female sex steroids are not found in normal menstrual cycles, except when the ovaries are hyperstimulated, as during assisted reproduction treatment (ART). During ART, patients with good ovarian reserve frequently respond well to exogenous gonadotrophins (FSH and LH), and very high levels of E 2 can commonly be observed before ovulation. Subsequently, elevated levels of progesterone (with concomitant high E 2 levels) can be observed in the luteal phase owing to the formation of multiple corpus lutea. Some previous reports have demonstrated that compromised embryo implantation rates could be observed in these patients, and detrimental effects on the implantation sites (the endometrium) were often incriminated.
Taken together, our study presented good evidence to support that high levels of E 2 and/or progesterone exerted suppressive effects on DcR3 in the endometrium. In the future, it will be interesting to test whether this suppressed DcR3 in the endometrium plays a role in the compromised implantation for patients with abnormally high E 2 /progesterone levels.
On the basis of the data involving serum DcR3 (peak level in the mid-luteal phase when embryo implantation normally occurs), the level of DcR3 protein in the decidua (decreased in anembryonic pregnancies) and abnormal DcR3 transcript expression (in endometrial cells when progesterone or E 2 levels are non-physiologically high), it is reasonable to speculate that an organized, physiologic regulation of DcR3 expression in the endometrium and decidua, at least partly by female sex steroids, may play a critical role in successful embryo implantation and placental formation.
